BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncogene

• Publication date

  2018-01-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41388-017-0063-5PMID 29326440
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

  2017cited by this paper
• MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

  2017cited by this paper
• Gab3 is required for human colorectal cancer cell proliferation.

  2017cited by this paper
• Investigating the utility of human melanoma cell lines as tumour models

  2017cited by this paper
• Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

  2017cited by this paper
• Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter

  2017cited by this paper
• Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels

  2017cited by this paper
• β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1

  2016cited by this paper
• Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations

  2016cited by this paper
• Small‐Molecule Stabilization of the 14‐3‐3/Gab2 Protein–Protein Interaction (PPI) Interface

  2016cited by this paper
• Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

  2016cited by this paper
• Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

  2016cited by this paper
• The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)

  2016cited by this paper
• The kinome 'at large' in cancer

  2016cited by this paper
• Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

  2016cited by this paper
• Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance

  2016cited by this paper
• Pan‐HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand‐induced EGFR homo‐ and heterodimers

  2016cited by this paper
• Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model

  2016cited by this paper
• Proteinase-activated Receptor 2 Promotes Cancer Cell Migration through RNA Methylation-mediated Repression of miR-125b*

  2015cited by this paper
• Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

  2015cited by this paper
• Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

  2015cited by this paper
• Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

  2015cited by this paper
• Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

  2015cited by this paper
• The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

  2015cited by this paper
• Gab2 is a novel prognostic factor for colorectal cancer patients.

  2015cited by this paper
• Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression

  2015cited by this paper
• A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

  2015cited by this paper
• Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

  2015cited by this paper
• Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

  2015cited by this paper
• Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma

  2015cited by this paper
• Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines

  2015cited by this paper
• MicroRNA‐409‐3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression

  2015cited by this paper
• The dynamic control of signal transduction networks in cancer cells

  2015cited by this paper
• B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.

  2015cited by this paper
• BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.

  2015cited by this paper
• Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.

  2015cited by this paper
• A comprehensive transcriptional portrait of human cancer cell lines

  2014cited by this paper
• BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

  2014cited by this paper
• Clinical Significance of GAB2, a Scaffolding/Docking Protein Acting Downstream of EGFR in Human Colorectal Cancer

  2014cited by this paper
• Molecular Pathways Molecular Pathways : HER 3 Targeted Therapy

  2014cited by this paper
• PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

  2014cited by this paper
• Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

  2014cited by this paper
• Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

  2013cited by this paper
• Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.

  2013cited by this paper
• Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors

  2013cited by this paper
• Role of GRB2‐associated binder 1 in epidermal growth factor receptor‐induced signaling in head and neck squamous cell carcinoma

  2013cited by this paper
• A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention

  2013cited by this paper
• Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

  2013cited by this paper
• Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

  2013cited by this paper
• Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition

  2013cited by this paper
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

  2013cited by this paper
• Functional characterization of cancer-associated Gab1 mutations

  2013cited by this paper
• Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells

  2013cited by this paper
• Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

  2013cited by this paper
• Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

  2013cited by this paper
• Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

  2012cited by this paper
• Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  2012cited by this paper
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

  2011cited by this paper
• Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells

  2011cited by this paper
• E3 ubiquitin ligases in ErbB receptor quantity control.

  2010cited by this paper
• Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Tumorigenesis and Neoplastic Progression Gab 2-Mediated Signaling Promotes Melanoma Metastasis

  2010cited by this paper
• Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

  2010cited by this paper
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• Function, regulation and pathological roles of the Gab/DOS docking proteins

  2009cited by this paper
• How to Grb2 a Gab.

  2009cited by this paper
• GAB2 Amplifications Refine Molecular Classification of Melanoma

  2009cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• EphB–ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells

  2007cited by this paper
• A role for the scaffolding adapter GAB2 in breast cancer

  2006cited by this paper
• Increased Proliferation and Altered Growth Factor Dependence of Human Mammary Epithelial Cells Overexpressing the Gab2 Docking Protein*

  2006cited by this paper
• EphB2 is a Prognostic Factor in Colorectal Cancer

  2005cited by this paper
• EphB receptor activity suppresses colorectal cancer progression

  2005cited by this paper
• Transcriptional regulation of AKT activation by E2F.

  2004cited by this paper
• Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers.

  2004cited by this paper
• PKB‐mediated negative feedback tightly regulates mitogenic signalling via Gab2

  2002cited by this paper
• The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation.

  1998cited by this paper
• Molecular Systems Biology 9; Article number 673; doi:10.1038/msb.2013.29 Citation: Molecular Systems Biology 9:673

  year unknowncited by this paper

• Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

  2025cites this paper
• Mortality Outcome Associated with Specific KRAS, NRAS, and BRAF Hot-Spot Mutations in Metastatic Colorectal Cancer Patients: A Retrospective Cohort Study

  2025cites this paper
• Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies

  2025cites this paper
• A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer

  2024cites this paper
• Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers

  2024cites this paper
• PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa‐2 cells via the inhibitions of p‐Akt/mTOR/NF‐κB and MMP2/MMP9 signaling pathways in vitro

  2024cites this paper
• BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

  2023cites this paper
• BRAF Non-V600 Mutations in Metastatic Colorectal Cancer

  2023cites this paper
• MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

  2023cites this paper
• MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.

  2023cites this paper
• Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report

  2023cites this paper
• Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

  2023cites this paper
• NETISCE: a network-based tool for cell fate reprogramming

  2022cites this paper
• Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.

  2022cites this paper
• AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis

  2022cites this paper
• Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells

  2022cites this paper
• Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer

  2021influential citation
• ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer

  2021cites this paper
• Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA

  2021cites this paper
• Cell-to-cell heterogeneities during extrinsic apoptosis arise from cell cycle progression and transmitotic apoptosis resistance

  2021cites this paper
• Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma

  2021cites this paper
• Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling

  2021influential citation
• SNHG7 has an oncogenic role in colorectal cancer via potential sponging of MIR-485-5P and MIR-193A-5P; in silico approach

  2021cites this paper
• EVI1 Promotes Metastasis by Downregulating TIMP2 in Metastatic Colon and Breast Cancer Cells.

  2021cites this paper
• Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis.

  2021cites this paper
• Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data

  2021cites this paper
• A Combinatorial Strategy for Tageting Papillary Thyroid Carcinoma with MEK Inhibitor and SHP2 Inhibitor

  2020cites this paper
• Cell Biology International

  2020cites this paper
• Modeling Adaptive Resistance of KRAS Mutant Colorectal Cancer to MAPK Pathway Inhibitors with a Three-Dimensional Tumor Model.

  2020cites this paper
• Unmet Medical Need in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutations: A Review

  2020cites this paper
• Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases

  2020cites this paper
• BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation

  2020cites this paper
• HER family in cancer progression: From discovery to 2020 and beyond.

  2020cites this paper
• RAF kinase dimerization: implications for drug discovery and clinical outcomes

  2020cites this paper
• Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges

  2020cites this paper
• Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

  2019influential citation
• Identification of genes and functional coexpression modules closely related to ulcerative colitis by gene datasets analysis

  2019influential citation
• Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains

  2019cites this paper
• Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments

  2019cites this paper
• BRAF Mutation and Its Importance in Colorectal Cancer

  2019cites this paper
• First‐line therapy for metastatic colorectal cancer: Current perspectives and future directions

  2019cites this paper
• Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology.

  2018cites this paper
• A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells*

  2017cites this paper